… Telephone 519-663-3344, fax 519-663-3232, e-mail melanie.beaton@lhsc.on.ca Received
… MD Beaton. current treatment options for nonalcoholic fatty liver disease and nonalcoholic …

There is no single pharmacologic therapy that has been approved to treat nonalcoholic fatty
liver disease in the general population. The backbone of therapy currently includes …

… Adams PC, Beaton MD. Transferrin saturation as a predictor of hepatic iron overload.
Liver … Beaton MD, Adams PC. Prognostic factors and survival in patients with hereditary …

… Beaton MD has served as an advisory board member or consultant for Abbvie, Allergan
and Takeda, and participated in clinical trials with Gilead and Intercept. The remaining authors …

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease in the Western
world, given its association with obesity, type 2 diabetes, and dyslipidemia. Medications are …

… Author contributions: Melanie D Beaton MD contributed to the study concept and design, …
MD contributed to the analysis and interpretation of liver histology data. Mark Levstik MD …

Purpose To validate a fully automated adipose segmentation method with magnetic
resonance imaging (MRI) fat fraction abdominal imaging. We hypothesized that this method is …

OBJECTIVES: The survival of treated, noncirrhotic patients with hereditary hemochromatosis
is similar to that of the general population. Less is known about the outcome of cirrhotic …

Background. In non-alcoholic fatty liver disease (NALFD), it has often been assumed that an
elevation in serum ferritin is likely related to inflammation rather than iron overload. Material …

OBJECTIVE To describe celiac disease (CD) screening rates and glycemic outcomes of a
gluten-free diet (GFD) in patients with type 1 diabetes who are asymptomatic for CD. …